LLY
Eli Lilly and Company
LLY has the edge over QGEN overall, supported by stronger modeled upside and stronger fundamentals.
QGEN
Qiagen N.V.
QGEN's outlook is improving, though it still trails on the overall score.
LLY Fundamentals
| Metric | Status |
|---|---|
| Healthy | |
| Strong | |
| Strong | |
| Healthy |
LLY's revenue, profitability, cash flow and balance sheet are all currently healthy.
QGEN Fundamentals
| Metric | Status |
|---|---|
| Stable | |
| Strong | |
| Healthy | |
| Healthy |
QGEN's profitability, cash flow and balance sheet are currently healthy, and its revenue is stable.
LLY PE Valuation
| Level | PE | Price | Vs current |
|---|---|---|---|
| Cheap | 27x | $845 | -41% |
| Forward | 30x | $1,427 | — |
| Current | 46x | $1,427 | — |
| Fair | 48x | $1,466 | +2.7% |
| Expensive | 85x | $2,612 | +83% |
Historical ranges are pointers, not guarantees.
LLY's PE is in its fair range at 46x. If earnings grow as analysts expect, today's price would be 30x next year's earnings, in its cheap range.
QGEN PE Valuation
| Level | PE | Price | Vs current |
|---|---|---|---|
| Forward | 20x | $50.10 | — |
| Cheap | 21x | $41.00 | -18% |
| Fair | 26x | $51.64 | +3.1% |
| Current | 26x | $50.10 | — |
| Expensive | 99x | $194 | +287% |
Historical ranges are pointers, not guarantees.
QGEN has the edge over LLY in the historical PE scenario, which offers more potential upside but is not a forecast.
LLY Forward outlook
| Metric | Outlook |
|---|---|
| Strongly improving | |
| Strong growth | |
| Strong growth | |
| Strongly improving | |
| Limited | |
| Moderate |
LLY has the edge over QGEN on the outlook, with more favorable profitability expectations.
QGEN Forward outlook
| Metric | Outlook |
|---|---|
| Strongly improving | |
| Growth | |
| Growth | |
| Stable | |
| Limited | |
| High |
Analysts expect earnings and revenue growth for QGEN, with profitability holding steady.
LLY Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Forward | $46.82 | +52% |
| Q3 2026 | $30.81 | +51% |
| Q2 2026 | $29.80 | +95% |
| Q1 2026 | $28.15 | +129% |
| Q4 2025 | $22.95 | +96% |
| Q3 2025 | $20.44 | +121% |
| Q2 2025 | $15.30 | +88% |
| Q1 2025 | $12.29 | +81% |
| Q4 2024 | $11.71 | +102% |
LLY's earnings per share have climbed steadily: $30.81 over the past year, up 51% from the year before, and higher year over year for 11 quarters in a row.
QGEN Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Forward | $2.54 | +30% |
| Q2 2026 | $1.95 | +15% |
| Q1 2026 | $1.89 | +340% |
| Q4 2025 | $1.97 | +418% |
| Q3 2025 | $1.86 | +354% |
| Q2 2025 | $1.70 | +431% |
| Q1 2025 | $0.43 | -72% |
| Q4 2024 | $0.38 | -75% |
| Q3 2024 | $0.41 | -72% |
QGEN earned $1.95 per share over the past year, up 15% from the year before.
LLY Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $24.4B | +39% |
| Q2 2026 | $23B | +48% |
| Q1 2026 | $19.8B | +56% |
| Q4 2025 | $19.3B | +43% |
| Q3 2025 | $17.6B | +54% |
| Q2 2025 | $15.6B | +38% |
| Q1 2025 | $12.7B | +45% |
| Q4 2024 | $13.5B | +45% |
LLY has the edge over QGEN on sales, with stronger typical year-over-year growth.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | 34% | -6.6 points |
| Q2 2026 | 40% | -3.3 points |
| Q1 2026 | 45% | +18 points |
| Q4 2025 | 43% | +5.6 points |
| Q3 2025 | 41% | +27 points |
| Q2 2025 | 44% | +12 points |
| Q1 2025 | 27% | -1.8 points |
| Q4 2024 | 37% | +10 points |
LLY has the edge over QGEN on profitability, with a higher operating margin.
QGEN Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q2 2026 | $535M | +0.3% |
| Q1 2026 | $492.3M | +1.8% |
| Q4 2025 | $540.4M | +3.7% |
| Q3 2025 | $532.6M | +6.1% |
| Q2 2025 | $533.5M | +7.5% |
| Q1 2025 | $483.5M | +5.4% |
| Q4 2024 | $521.2M | +2.4% |
| Q3 2024 | $501.9M | +5.5% |
QGEN's revenue has grown year over year for nine quarters in a row: $535M last quarter, about level with the same quarter a year ago.
| Quarter | Margin | YoY |
|---|---|---|
| Q2 2026 | 25% | +1.9 points |
| Q1 2026 | 24% | -0.2 points |
| Q4 2025 | 28% | +5.6 points |
| Q3 2025 | 24% | +1.9 points |
| Q2 2025 | 23% | +69 points |
| Q1 2025 | 24% | +3.2 points |
| Q4 2024 | 23% | +1.1 points |
| Q3 2024 | 22% | +1.9 points |
QGEN's operating margin was 25% last quarter, up 1.9 points from the same quarter a year ago.
LLY Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | $8.2B | +22% |
| Q2 2026 | $7.8B | +458% |
| Q1 2026 | $3B | +1826% |
| Q4 2025 | $677.9M | -31% |
| Q3 2025 | $6.7B | +186% |
| Q2 2025 | $1.4B | +476% |
| Q1 2025 | $156.1M | -13% |
| Q4 2024 | $977.8M | +$2.4B |
LLY has the edge over QGEN on cash flow, with more consistent year-over-year improvement.
QGEN Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q2 2026 | $157.8M | +31% |
| Q1 2026 | $53.7M | -44% |
| Q4 2025 | $117.2M | -17% |
| Q3 2025 | $119M | -14% |
| Q2 2025 | $120.6M | -5.6% |
| Q1 2025 | $95.8M | +1.2% |
| Q4 2024 | $141.9M | +43% |
| Q3 2024 | $138M | +65% |
QGEN generated $448M in free cash flow over the past year, down 9.8% from the year before.
LLY Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | 0% | -300K shares |
| 1 year | -0.6% | -5.4M shares |
| 3 years | -0.7% | -6.4M shares |
| 5 years | -1.9% | -17.4M shares |
| Available history | -4.5% | -42.3M shares |
LLY has 893M diluted shares, down 0.6% from a year ago.
| Quarter | Spent |
|---|---|
| Q3 2026 | $377M |
| Q2 2026 | $1.6B |
| Q1 2026 | $2.4B |
| Q4 2025 | $1.5B |
| Q3 2025 | $708.1M |
| Q2 2025 | $692.2M |
| Q1 2025 | $1.2B |
| Q4 2024 | $2.1B |
LLY spent $5.8B buying back its own shares over the past year, up 26% from the year before.
QGEN Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | -0.5% | -1.1M shares |
| 1 year | -4.7% | -10.4M shares |
| 3 years | -7.1% | -15.8M shares |
| 5 years | -10% | -24.1M shares |
| Available history | -8.3% | -18.7M shares |
QGEN has the edge over LLY on shareholder dilution, with a more favorable share count trend.
| Quarter | Spent |
|---|---|
| Q2 2026 | — |
| Q1 2026 | $496.7M |
| Q4 2025 | $2.7M |
| Q3 2025 | $9.3M |
| Q2 2025 | $10.3M |
| Q1 2025 | $280.1M |
| Q4 2024 | $906,000 |
| Q3 2024 | $6.2M |
QGEN spent $509M buying back its own shares over the past year, up 71% from the year before.
LLY Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q3 2026 | 1.2x | Healthy |
| Q2 2026 | 1.3x | Healthy |
| Q1 2026 | 1.2x | Healthy |
| Q4 2025 | 1.3x | Healthy |
| Q3 2025 | 1.3x | Healthy |
| Q2 2025 | 2.0x | Healthy |
| Q1 2025 | 2.3x | Moderate |
| Q4 2024 | 2.1x | Moderate |
LLY's net debt is about 1.2 years of its operating earnings (EBITDA), about the same as a year ago.
QGEN Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q2 2026 | 1.2x | Healthy |
| Q1 2026 | 1.4x | Healthy |
| Q4 2025 | 1.1x | Healthy |
| Q3 2025 | 1.1x | Healthy |
| Q2 2025 | 1.0x | Very low |
| Q1 2025 | 2.1x | Moderate |
| Q4 2024 | 2.6x | Moderate |
| Q3 2024 | 2.6x | Moderate |
QGEN's net debt is about 1.2 years of its operating earnings (EBITDA), up from a year a year ago.
LLY Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 68.3 | Neutral |
| Stochastic | 84.1 | Overbought |
LLY's weekly RSI is 68 (neutral) and its Stochastic is 84 (overbought).
QGEN Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 71.4 | Overbought |
| Stochastic | 92.8 | Overbought |
QGEN's weekly RSI is 71 (overbought) and its Stochastic is 93 (overbought).
LLY PE vs Healthcare Sector
| Metric | LLY | Sector median | Relative |
|---|---|---|---|
| PE | 46x | 26x | 79% above |
| PE % | 48 | 29 | 19 pts above |
LLY is trading at 46x earnings, a 79% premium to the Healthcare sector's median of 26x.
QGEN PE vs Healthcare Sector
| Metric | QGEN | Sector median | Relative |
|---|---|---|---|
| PE | 26x | 26x | 0.6% below |
| PE % | 44 | 29 | 15 pts above |
QGEN has the edge over LLY on valuation relative to its sector.
LLY Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $1,279.4 | 12% above |
| 20 week MA | $1,218.8 | 17% above |
| 50 week MA | $1,102.2 | 29% above |
| 100 week MA | $954.1 | 50% above |
| 200 week MA | $797.5 | 79% above |
LLY is in an uptrend: it's above all five of its weekly moving averages, and 79% above its 200-week average.
QGEN Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $47.7 | 5.1% above |
| 20 week MA | $44.4 | 13% above |
| 50 week MA | $43.5 | 15% above |
| 100 week MA | $44.1 | 14% above |
| 200 week MA | $43.9 | 14% above |
QGEN is in an uptrend: it's above all five of its weekly moving averages, and 14% above its 200-week average.
LLY Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $131.5 | $166.7 | +27% |
| 2021 | $166.7 | $273.1 | +64% |
| 2022 | $273.1 | $367.9 | +35% |
| 2023 | $367.9 | $582.9 | +58% |
| 2024 | $582.9 | $783.2 | +34% |
| 2025 | $783.2 | $1,077.8 | +38% |
| 2026 YTD | $1,077.8 | $1,427.3 | +32% |
LLY has the edge over QGEN on returns for 2026, with the stronger performance.
QGEN Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $33.9 | $52.6 | +55% |
| 2021 | $52.6 | $55.7 | +5.8% |
| 2022 | $55.7 | $49.7 | -11% |
| 2023 | $49.7 | $43.8 | -12% |
| 2024 | $43.8 | $44.0 | +0.5% |
| 2025 | $44.0 | $47.8 | +8.6% |
| 2026 YTD | $47.8 | $50.1 | +4.9% |
QGEN has finished higher in four of the last six years. It's up 4.9% so far in 2026.